Lymphoma Treatment Guidelines
Diagnosis and Staging
- The initial treatment approach for patients diagnosed with lymphoma should be based on the specific lymphoma subtype, disease stage, and patient characteristics, with proper classification and staging being essential, including an adequate tissue biopsy, staging according to the Ann Arbor classification system, and a complete workup 1
- A complete workup includes a CT scan of neck, thorax, abdomen, and pelvis, bone marrow aspirate and biopsy, PET-CT, complete blood count, LDH, β2-microglobulin, and other routine blood chemistry, as well as screening for HIV, HBV, and HCV 1
Treatment Approaches
- Radiotherapy (ISRT, 24-30 Gy) is the preferred approach with curative intent for certain lymphoma types 1
- For asymptomatic patients with low tumor burden, a watch and wait approach is recommended 2
- For symptomatic patients or high tumor burden, rituximab plus chemotherapy is recommended, with common regimens including R-CHOP, R-CVP, and R-bendamustine 2
- The European Society for Medical Oncology recommends shortened conventional chemotherapy followed by consolidation radiotherapy for certain patients 3
- For elderly patients, immunochemotherapy (R-CHOP, R-bendamustine, VR-CAP) is recommended, while for younger/fit patients, cytarabine-containing induction followed by autologous stem cell transplantation is recommended 3
- The standard treatment is 6-8 cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) given every 21 or 14 days 4
Treatment Considerations
- Dose intensity should be maintained whenever possible, and growth factor support should be considered to prevent febrile neutropenia 4
- Dose reductions due to hematological toxicity should be avoided in patients treated with curative intent 4
- Age-appropriate dose adjustments may be necessary, and comorbidities should be considered when selecting a treatment regimen 3
- Targeted approaches, such as Bruton's tyrosine kinase inhibitors for MCL, lenalidomide-rituximab for FL and MCL, PI3K inhibitors for relapsed FL, and CAR T-cell therapy for relapsed aggressive lymphomas, should be considered 3
Response Assessment and Follow-up
- Radiological tests should be performed after 2-4 cycles and at the end of treatment, and PET-CT should be considered for response assessment, particularly for DLBCL 4
- Bone marrow biopsy should be repeated at the end of treatment if initially involved 4